OncoMatch/Clinical Trials/NCT07762976
Dynamic Risk-adapted EBV-DNA and MRI-guided De-concurrent Chemotherapy in Nasopharyngeal Carcinoma
Is NCT07762976 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies Adjuvant therapy for nasopharyngeal carcinoma (npc).
Treatment: Adjuvant therapy — This study aims to explore the efficacy and safety of risk-adapted adjuvant therapy based on dynamic EBV-DNA changes and MRI in nasopharyngeal carcinoma patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: EBV dna > 0 (positive)
Baseline plasma EBV-DNA > 0, and able to complete dynamic monitoring according to the protocol.
Disease stage
Required: Stage II, III
Excluded: Stage T3N0M0 (ONLY POSTERIOR PHARYNGEAL LYMPH NODE METASTASIS), T3N1M0
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: chemotherapy
Before the diagnosis of nasopharyngeal carcinoma, the patient had received chemotherapy
Cannot have received: targeted therapy
Before the diagnosis of nasopharyngeal carcinoma, the patient had received ... targeted therapy
Cannot have received: immunotherapy
Before the diagnosis of nasopharyngeal carcinoma, the patient had received ... immunotherapy
Cannot have received: radiotherapy for head and neck tumors
Exception: except for diagnostic biopsies
had a history of radiotherapy or surgery for head and neck tumors (except for diagnostic biopsies)
Cannot have received: surgery for head and neck tumors
Exception: except for diagnostic biopsies
had a history of radiotherapy or surgery for head and neck tumors (except for diagnostic biopsies)
Lab requirements
Blood counts
neutrophils ≥ 2.0×10^9/l, platelets ≥ 100×10^9/l, hemoglobin ≥ 90 g/l
Kidney function
creatinine clearance rate ≥ 60 ml/min
Liver function
alt/ast ≤ 1.5×uln, total bilirubin ≤ 1.5×uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07762976 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require EBV?
Yes, EBV dna > 0 is a required biomarker for enrollment.
What disease stage is eligible?
Stage II or III is required.
Is there an age limit?
Yes. Patients must be 65 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages